You are here: Industry Insights > Valeant

News List

Valeant's fourth-quarter loss widens as sales slip 13 percent firstwordpharma
March 01, 2017
Valeant Pharmaceuticals' fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales dropped 13 percent year-over-year to $2.4 billion, the company reported Tuesday.
Valeant and EyeGate sign licensing agreement pharmaceutical-technology
February 24, 2017
Valeant Pharmaceuticals has signed an agreement for global commercial and manufacturing rights to US-based EyeGate Pharmaceuticals’ new technology and EGP-437 combination product candidate to treat post-operative pain and inflammation in occular surgery p
Valeant to sell Dendreon to China’s Sanpower for $819.9m pharmaceutical-technology
January 13, 2017
Canada’s Valeant Pharmaceuticals’ affiliate has entered into an agreement to sell its equity interests in Dendreon Pharmaceuticals to China’s Sanpower Group for $819.9m.
Valeant to sell Dendreon cancer business to Sanpower for $820 million firstwordpharma
January 11, 2017
Valeant Pharmaceuticals announced that it reached an agreement to sell all of its outstanding equity interests in its Dendreon cancer business to Chinese conglomerate Sanpower Group for $820 million in cash.
Valeant to Sell CeraVe, AcneFree and AMBI Skincare Brands to L'Oreal for $1.3B americanpharmaceuticalreview
January 11, 2017
Valeant Pharmaceuticals has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The CeraVe, AcneFree, and AMBI product lines have annualized revenue of approximately of $168M.

Previous page 1 2 3 Next page